Search Results

1 - 10 of 136 items :

  • "pulmonary hypertension" x
Clear All

References 1. Benjaminov FS. Portopulmonary hypertension in decompensated cirrhosis with refractory ascites. Gut. 2003;52(9):1355-1362. doi:10.1136/gut.52.9.1355 2. Kawut SM, Krowka MJ, Trotter JF, et al. Clinical risk factors for portopulmonary hypertension. Hepatology. 2008;48(1):196-203. doi:10.1002/hep.22275 3. Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and

References 1. J. K. Liao and U. Laufs, Pleiotropic effects of statins, Annu. Rev. Pharmacol. Toxicol. 45 (2005) 89-118; DOI: 10.1146/annurev.pharmtox.45.120403.095748. 2. S. Wolfrum, K. S. Jensen and J. K. Liao, Endothelium-dependent effects of statins, Arterioscler. Thromb. Vasc. Biol. 23 (2003) 729-736; DOI: 10.1161/01.ATV.0000063385.12476.A7. 3. L. Taraseviciene-Stewart, R. Scerbavicius, K. H. Choe, C. Cool, K. Wood, R. M. Tuder, N. Burns, M. Kasper and N. F. Voelkel, Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension

References [1] Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA. A highly efficacious lymphocyte chemoattractant, stromal cellderived factor 1 (SDF-1). J Exp Med. 1996;184(3):1101-9. [2] Bogaard HJ, Abe K, Vonk Noordegraaf A, Voelkel NF. The right ventricle under pressure: cellular and molecular mechanisms of right-heart failure in pulmonary hypertension. Chest. 2009;135(3):794-804. [3] Burke DL, Frid MG, Kunrath CL et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung

References [1] Galiè N, Humbert M, Vachiery J-L, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016;37:67-119. [2] Madani MM, Auger WR, Pretorius V, et al. Pulmonary endarterectomy: recent changes

References 1. Avey JB . Pulmonary hypertension. In: Cardiovascular Pathology in Infants and Children by JB Avey Saunders Company 1984 2. Stocker JT, Dehner LP.: Pulmonary hypertension in Pediatric Pathology by Stocker JT & Dehner LP., Lippincott Company, 1992 3. McLaughlin VV, McGoon MD: Pulmonary arterial hypertension. Circulation 2006, 114, 1417-1432 4. Travis WD, Colby TV, Koss MN, Rosado-de-Christenson ML, Muller NL, King TEJr, Non-Neoplastic Disorders of the Lower Respiratory Tract, 2002, 5. Badesch DB, Champion HC, Sanches MA et al.: Diagnosis and

References Becattini, C., Agnelli, G., Pesavento, R., Silingardi, M., Poggio, R., Taliani, M. R. (2006). Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. Chest., 130 (1), 172-175. Blauwet, L. A., Edwards, W. D., Tazelaar, H. D., McGregor, C. G. A. (2003). Surgical pathology of pulmonary thromboendarterectomy. Hum. Pathol., 34, 1290-1298. Corsico, A. G., D’ Armini, A. M., Cerveri, I., Klersy, C., Ansaldo, E., Niniano, R. (2008). Long-term outcome after pulmonary endarterectomy. Amer. J. Respir. Crit. Care Med

analogues in pulmonary arterial hypertension: Role of membrane versus nuclear receptors. Prostaglandins & Other Lipid Mediators , 120 , 56–71. https://doi.org/10.1016/j.prostaglandins.2015.04.007 [4] Fleming, I., & Busse, R. (1999). Signal transduction of eNOS activation. Cardiovascular Research , 43 (3), 532–41. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10690325 [5] Galiè, N., Humbert, M., Vachiery, J.-L., Gibbs, S., Lang, I., Torbicki, A., … Luis Zamorano, J. (2016). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension

References 1. Walsh-Sukys MC, Tyson JE, Wright LL, Bauer CR, Korones SB, Stevenson DK, et al. Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics. 2000; 105:14-20. 10.1542/peds.105.1.14 2. Nakwan N, Nakwan N, Wannaro J. Predicting mortality outcome in infants with persistent pulmonary hypertension of the newborn with the Score for Neonatal Acute Physiology-Version II (SNAP-II) in Thai neonates. J Perinat Med. 2011; 39:311-5. 3. Vargas-Origel A, Gomez-Rodríguez G, Aldana- Valenzuela C, Vela

References 1. Stepien RL: Pulmonary arterial hypertension secondary to chronic left-sided cardiac dysfunction in dogs. J Small Anim Pract 2009, 50-SUPPL 1:34-43. 2. Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna M, Langleben D, Manes A, Satoh T, Torres F, Wilkins MR, Badesch DB: Defi nitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013, 62(25 SUPPL):D42-D50. 3. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A

References 1. Jenkins, D. (2015). Pulmonary endarterectomy: the potentially curative treatment for patients with chronic thromboembolic pulmonary hypertension. Eur Respir Rev, 24(136), 263-271. doi: 10.1183/16000617.00000815 2. Kim, N.H., Delcroix, M., Jenkins, D.P., Channick, R., Dartevelle, P., Jansa, P., Lang, I., Madani, M.M., Ogino, H., Pengo, V., & Mayer, E. (2013). Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol, 62(25 Suppl), D92-99. doi: 10.1016/j.jacc.2013.10.024. 3. Galie, N., Humbert, M., Vachiery, J.L., Gibbs, S., Lang, I